Functional assessment of CYP3A4 and CYP2C19 genetic polymorphisms on the metabolism of clothianidin in vitro

被引:0
|
作者
Hu, Yingying [1 ]
Ye, Zhize [2 ]
Wu, Hualu [1 ]
Chen, Xiaohai [1 ]
Xia, Hailun [1 ]
Cai, Jian-ping [3 ]
Hu, Guo-xin [4 ]
Xu, Ren-ai [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Nanbaixiang St, Wenzhou 325000, Zhejiang, Peoples R China
[2] Shaoxing Peoples Hosp, Shaoxing, Zhejiang, Peoples R China
[3] Chinese Acad Med Sci, Inst Geriatr Med, Key Lab Geriatr,Beijing Inst Geriatr, Beijing Hosp,Natl Ctr Gerontol,Natl Hlth Commiss, Beijing, Peoples R China
[4] Wenzhou Med Univ, Inst Mol Toxicol & Pharmacol, Sch Pharmaceut Sci, Wenzhou, Zhejiang, Peoples R China
关键词
Clothianidin; Variants; Metabolism; ALLELIC VARIANTS; RAPID METABOLIZER; IDENTIFICATION; GENOTYPE; EXPOSURE; ENZYMES; RISK;
D O I
10.1016/j.cbi.2024.111154
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Clothianidin, classified as a second-generation neonicotinoid, has achieved extensive application due to its high efficacy against insect pests. This broad-spectrum usage has resulted in its frequent detection in environmental surveys. CYP2C19 and CYP3A4 are crucial for converting clothianidin to desmethyl-clothianidin (dm-clothianidin). The expression of these CYP450s can be significantly influenced by genetic polymorphisms. The objective of our research was to examine the catalytic effects of 27 CYP3A4 variants and 31 CYP2C19 variants on the metabolism of clothianidin within recombinant insect microsomes. These variants were assessed through a wellestablished incubation procedure. In addition, the concentration of its metabolite dm-clothianidin was quantified by employing an ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Lastly, the kinetic parameters of these CYP3A4 and CYP2C19 variants were calculated by applying Michaelis-Menten kinetic analysis to fit the data. The observed changes in enzyme activity were related to the metabolic transformation of clothianidin to dm-clothianidin. In the CYP2C19 metabolic pathway, one variant (CYP2C19.23) showed no notable change in intrinsic clearance (CLint), four variants (CYP2C19.29, .30, .31 and L16F) demonstrated a marked increase in CLint(110.86-183.46 %), and the remaining 25 variants exhibited a considerable decrease in CLint(26.38-89.79 %), with a maximum decrease of 73.62 % (CYP2C19.6). In the CYP3A4 metabolic pathway, 26 variants demonstrated significantly reduced CLint(10.54-52.52 %), with a maximum decrease of 89.46 % (CYP3A4.20). Our results suggested that most variants of CYP3A4 and CYP2C19 significantly altered the enzymatic activities associated with clothianidin metabolism to various degrees. This study provides new insights into assessing the metabolic behavior of pesticides and delivers crucial data that can guide clinical detoxification strategies.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] CYP3A4 and CYP2C19 genetic polymorphisms and myricetin interaction on tofacitinib metabolism
    Ye, Zhize
    Xia, Hailun
    Hu, Jinyu
    Liu, Ya-nan
    Wang, Anzhou
    Cai, Jian-ping
    Hu, Guo-xin
    Xu, Ren-ai
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [2] CYP3A4 and CYP2C19 genetic polymorphisms and zolpidem metabolism in the Chinese Han population: A pilot study
    Shen, Min
    Shi, Yan
    Xiang, Ping
    FORENSIC SCIENCE INTERNATIONAL, 2013, 227 (1-3) : 77 - 81
  • [3] Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism
    Yuan, Ling-Jing
    Li, Xiang-Yu
    Ni, Jin-Huan
    Wang, Jing
    Xu, Xiao-Yu
    Luo, Jian-Chao
    Zhou, Qi
    Hu, Guo-Xin
    Cai, Jian-Ping
    Qian, Jian-Chang
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2023, 475
  • [4] Metabolism of tilidine by human liver microsomes, CYP3A4 and CYP2C19
    Sawa, E.
    Riedel, K. D.
    Haefeli, W. E.
    Mikus, G.
    Weiss, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2007, 101 (05) : 377 - 377
  • [5] INFLUENCE OF CYP2C19 AND CYP3A4 ON TILIDINE PHARMACOKINETICS AND METABOLISM IN HUMANS
    Merkel, U.
    Riedel, K. -D.
    Gruen, B.
    Mikus, G.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 : 22 - 22
  • [6] Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro
    Stage, Tore Bjerregaard
    Graff, Magnus
    Wong, Susan
    Rasmussen, Louise Ladebo
    Nielsen, Flemming
    Pottegard, Anton
    Brosen, Kim
    Kroetz, Deanna L.
    Khojasteh, Cyrus
    Damkier, Per
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (03) : 510 - 519
  • [7] Prevalence of CYP2C19, CYP3A4 and FMO3 genetic polymorphisms in healthy northeastern Thai volunteers
    Areesinpitak, Thikhumporn
    Kanjanawart, Sirimas
    Nakkam, Nontaya
    Tassaneeyakul, Wichittra
    Vannaphasaht, Suda
    SCIENCEASIA, 2020, 46 (04): : 397 - 402
  • [8] Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians
    Kohlrausch, Fabiana B.
    Carracedo, Angel
    Hutz, Mara H.
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (03) : 1453 - 1460
  • [9] Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians
    Fabiana B. Kohlrausch
    Ángel Carracedo
    Mara H. Hutz
    Molecular Biology Reports, 2014, 41 : 1453 - 1460
  • [10] Mechanism-based inactivation (MBI) of recombinant CYP2C19 and CYP3A4 but not human liver microsomal CYP2C19 and CYP3A4 by nortriptyline
    Polasek, Thomas M.
    Miners, John O.
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 234 - 234